MINNEAPOLIS, Feb. 11 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (AMEX:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that the Urgent(R) PC Neuromodulation System, its proprietary, minimally invasive nerve stimulation device, designed for office-based treatment of overactive bladder (OAB) symptoms, will be featured in three presentations at the Society of Urologic Nurses and Associates (SUNA) Annual Symposium. SUNA will be held at the Marriott Waterside Hotel and Marina in Tampa, Florida from Thursday, February 28, through Sunday, March 2. These retrospective and observational studies examined the use of Urgent(R) PC Neuromodulation System to deliver the percutaneous tibial nerve stimulation (PTNS) for the treatment of OAB symptoms of urinary urgency, urinary frequency, and urge incontinence. The Company will present a summary of these presentations on Monday, March 3 before the market opens. The schedule for the oral presentation and poster-discussion sessions is as follows: -- Leslie Wooldridge, MSN, RNCS, GNP.F, BCIA-PMBD, Director of the Bladder
Control Clinic, Hackley Health at the Lakes Women's Center, Muskegon,
Michigan, "Percutaneous Tibial Nerve Stimulation: Revival of an Old
Technology for Treatment of Overactive Bladder," Sunday, March 2, at 8
am, oral presentation -- Vanessa K. Hardy, WHNP, APN, MSN, Nurse Practitioner, Urogynecology,
Vanderbilt University Medical Center, Nashville, Tennessee,
"Percutaneous Tibial Nerve Stimulator: A Viable Option for Urgency,
Frequency, and Urge Incontinence," Friday, February 29 through
Saturday, March 1, poster presentation -- Lesbia Candelaria, RN, Winter Park Urology Associates, Orlando,
Florida, "Percutaneous Tibial Nerve Stimulation (PTNS) Treatment for
Overactive Bladder (OAB) Patients in a Community Based Urology
Practice," Friday, February 29 through Saturday, March 1, poster
presentation
About the Urgent PC Neuromodulation System
The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA- approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com/.
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
952.426.6140 EVC Group
Julie Huang/Matt Selinger (Investors)
646.443.6963
Steve DiMattia/Chris Gale (Media)
646.201.5445
DATASOURCE: Uroplasty, Inc.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors, Julie Huang or Matt Selinger, +1-646-443-6963, or Media, Steve DiMattia or Chris Gale, +1-646-201-5445, all of EVC Group, for Uroplasty, Inc.
Web site: http://www.uroplasty.com/
|